| 糖尿病视网膜病变药物治疗的研究进展 |
| |
| 引用本文： | 刘朝辉,高晓虹,栗改云,马涛,李康. 糖尿病视网膜病变药物治疗的研究进展[J]. 国际眼科纵览, 2016, 0(4): 272-276. DOI: 10.3760/cma.j.issn.1673-5803.2016.04.012 |
| |
| 作者姓名： | 刘朝辉 高晓虹 栗改云 马涛 李康 |
| |
| 作者单位： | 1. 山西医科大学, 太原,030001;2. 山西省眼科医院, 太原,030002 |
| |
| 摘 要： | 随着糖尿病视网膜病变(diabetic retinopathy,DR)发病机制的深入研究,目前对DR的药物治疗取得了一定的成果,包括糖皮质激素、抗血管内皮细胞生长因子、抗血小板源性生长因子、非甾体类消炎药以及改善视神经功能的药物.目前治疗糖尿病黄斑水肿,玻璃体注药治疗特别是抗血管内皮细胞生长因子药物已逐渐推广.
|
| 关 键 词： | 糖尿病视网膜病变 糖皮质激素 血管内皮生长因子 血小板源性生长因子 |
Progress in medication for diabetic retinopathy |
| |
| Abstract: | With the update of the pathologic mechanisms of diabetic retinopathy (DR),currently medication therapy has also made some progress,including corticosteroids,anti-vascular endothelial growth factor,anti-platelet derived growth factor,non-steroidal anti-inflammatory drugs,as well as drugs to improve the function of the optic nerve.Currently,in the treatment of diabetic macular edema,intravitreal pharmacotherapies,especially anti-vascular endothelial growth factor (anti-VEGF) agents,have gained popularity. |
| |
| Keywords: | diabetic retinopathy corticosteroids vascular endothelial growth factor platelet-derived growth factor |
| 本文献已被 万方数据 等数据库收录！ |
|
